Antimicrobial Stewardship in Pediatrics

Introduction And Rationale

Antimicrobial Resistance (AMR) poses a critical threat to vulnerable pediatric cohorts, particularly extreme premature neonates, primary immunodeficiency patients, and oncology patients.
Unnecessary broad-spectrum antibiotic exposure disrupts the developing infant gut microbiome, causing dysbiosis linked to long-term adverse outcomes such as pediatric obesity, asthma, and atopic dermatitis.
Antimicrobial Stewardship Programs (ASPs) aim to optimize drug selection, dose, route, and duration, accounting for dynamic, age-dependent pediatric pharmacokinetics and pharmacodynamics (PK/PD).

Effective ASPs require hospital leadership commitment, protected time, and a multidisciplinary team involving a pediatric infectious disease specialist, clinical pharmacist, microbiologist, and infection control nurse.

Core Element	Intervention Strategy
Prospective Audit And Feedback (PAF)	Known as "Handshake" stewardship; involves direct engagement with prescribing pediatricians to suggest modifications or de-escalation based on culture sensitivities.
Formulary Restriction	Preauthorization is mandated for WHO "Reserve" category antibiotics (e.g., Colistin, Cefiderocol, Ceftazidime-avibactam) to restrict use to confirmed multi-drug resistant infections.
Tracking And Reporting	Tracking standardizes consumption data using "Days of Therapy" (DOT) per 1000 patient days to benchmark across PICUs and NICUs.
Clinical Decision Support Systems (CDSS)	Integrating pediatric-specific dosing guidelines and local antibiograms directly into the Electronic Medical Record (EMR).

Diagnostic stewardship ensures ordering the right test at the right time to guide therapeutic interventions.
Rapid syndromic multiplex PCR (e.g., BioFire FilmArray) identifies over 20 specific respiratory or gastrointestinal pathogens in under an hour, facilitating rapid cessation of empiric antibiotics.
Point-of-Care molecular platforms (Truenat, GeneXpert) provide rapid genotypic resistance data (mecA, blaNDM), allowing precise targeted therapy from the first dose.
Advanced host-response biomarkers (transcriptomics) distinguish bacterial from viral immune responses with high sensitivity, providing an objective rationale to withhold antibiotics in virally infected infants.
Artificial Intelligence predictive models analyze historical data and local antibiograms to suggest personalized empirical regimens.
Automated Therapeutic Drug Monitoring (TDM) using Bayesian forecasting requires fewer blood draws, optimizing exposure for Vancomycin and Aminoglycosides while preventing nephrotoxicity and ototoxicity.

IDSA Guidelines (2025-2026): The Surviving Sepsis Campaign mandates protocolized reassessment at 48 to 72 hours, promoting rapid de-escalation if blood cultures remain negative. Endorses a major shift toward short-course therapies (3-5 days) for uncomplicated community-acquired pneumonia (CAP) and UTIs.
IAP Guidelines: Mandates empirical therapy based strictly on local antibiograms. Discourages irrational fixed-dose combinations (e.g., Ofloxacin + Ornidazole) for acute viral gastroenteritis. Promotes the WHO AWaRe (Access, Watch, Reserve) classification to prioritize "Access" group antibiotics.
National Initiatives: The National Action Plan on Antimicrobial Resistance (NAP-AMR) enforces ASP establishment in all tertiary care hospitals. ASPs must be coupled with rigorous Infection Prevention and Control (IPC) programs utilizing hand hygiene and central line care bundles.